Vanguard Capital Management
ALZN icon

Vanguard Capital Management’s Alzamend Neuro ALZN Stock Holding History

Vanguard Capital Management’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.07K Buy
7,556
+3,156
+72% +$3.5K ﹤0.01% 4052
2026
Q1 		$4.66K Buy
+4,400
New +$8.79K ﹤0.01% 4037

Other funds holding ALZN

KWM
KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IA
IFG Advisory Atlanta, Georgia $2.85B AUM 26.07% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

Vanguard Capital Management's ALZN Position: Q2 2026 in Review

Vanguard Capital Management increased its Alzamend Neuro (ALZN) stake by 72% in Q2 2026, buying an estimated $3.5K and bringing the position to 7,556 shares worth $9.07K. The position accounts for ﹤0.01% of the portfolio, ranked #4052.

Vanguard Capital Management first reported a position in ALZN in Q1 2026 and has held it in 2 quarters since. 11 funds tracked by Wall St. Rank hold ALZN as of Q2 2026.

  • Vanguard Capital Management held 7,556 shares of Alzamend Neuro worth $9.07K as of Q2 2026.
  • Vanguard Capital Management bought 3,156 Alzamend Neuro shares in Q2 2026, an estimated $3.5K.
  • Alzamend Neuro made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #4052 holding.
  • Vanguard Capital Management first reported a position in Alzamend Neuro in Q1 2026 and has held it in 2 quarters since.
  • 11 funds tracked by Wall St. Rank held Alzamend Neuro as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.